Navigation Links
Aton Pharma Acquires U.S. TIMOPTIC(R)

LAWRENCEVILLE, N.J., Feb. 25 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has acquired the U.S. marketing rights to the TIMOPTIC(R) product line from Merck & Co., Inc. TIMOPTIC (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. As many as 2.25 million Americans suffer from open-angle glaucoma.

The U.S. TIMOPTIC product line includes TIMOPTIC(R) (timolol maleate) Ophthalmic Solution, TIMOPTIC (timolol maleate ophthalmic solution) in OCUDOSE(R) (sterile ophthalmic unit dose dispenser) and TIMOPTIC-XE(R) (timolol maleate ophthalmic gel forming solution) Ophthalmic. TIMOPTIC in OCUDOSE(R) is the only preservative-free medication for glaucoma available in the U.S. and aligns with Aton's strategy of providing unique, medically essential products.

Aton Pharma also provides the dry eye medication LACRISERT(R) (hydroxypropyl cellulose ophthalmic insert), a preservative-free, once-daily*, sustained release prescription insert indicated for moderate to severe dry eye, that helps to retain moisture, stabilize the tear film, and lubricate the eye.

"Aton has made the strategic decision to expand our commitment within the field of ophthalmology," stated Michael G. Wells, Chief Executive Officer of Aton Pharma. "The acquisition of the U.S. TIMOPTIC franchise significantly enhances our profile within the ophthalmology community while enabling us to serve yet another niche market that is greatly underserved."

"A large body of evidence has indicated that ocular preservatives, particularly benzalkonium chloride (BAK), impair surface tissues of the eye leading to inflammation, dry eye and other issues," explained Penny Asbell, M.D., Professor of Ophthalmology at Mount Sinai School of Medicine. "This is particularly problematic in glaucoma patients, who must use medication frequently and for long periods of time. Preservative-free product options are important for these patients with dry eyes."**

Aton's market research indicates that more than 60% of ophthalmologists are unaware that preservative-free preparations of timolol are available. The use of preservative-containing glaucoma medications in patients with compromised ocular surface issues is of particular concern to nearly 80% of ophthalmologists.

"As we have done with LACRISERT and other Aton products, we will concentrate on enhancing distribution, sampling and reimbursement assistance while increasing patient and provider awareness for TIMOPTIC in OCUDOSE(R)," added Mr. Wells.

TIMOPTIC in OCUDOSE(R), along with TIMOPTIC(R) and TIMOPTIC XE(R), is indicated for the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. TIMOPTIC in OCUDOSE(R) , TIMOPTIC(R), and TIMOPTIC-XE(R) are contraindicated in patients with bronchial asthma; a history of bronchial asthma; severe chronic obstructive pulmonary disease; sinus bradycardia; second or third degree atrioventricular block; overt cardiac failure; cardiogenic shock; or hypersensitivity to any component of this product. Because of the potential effects of beta-adrenergic blocking agents on blood pressure and pulse, these agents should be used with caution in patients with cerebrovascular insufficiency. The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical ophthalmic administration.

LACRISERT is indicated in patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. Most adverse reactions with LACRISERT were mild and transient and included transient blurring of vision, ocular discomfort or irritation, matting or stickiness of eyelashes, photophobia, hypersensitivity, edema of the eyelids, and hyperemia. LACRISERT should not be used by patients who are hypersensitive to hydroxypropyl cellulose. If improperly placed, LACRISERT may result in corneal abrasion.

About Aton Pharma, Inc.

Aton Pharma, Inc., headquartered in Lawrenceville, NJ, is a global, diversified specialty pharmaceutical company providing essential treatments for under-treated diseases. Aton's mission is to improve patient outcomes and quality of life worldwide by enhancing and expanding access and availability of medically essential therapeutics. Aton's portfolio of ten products, with sales in over 30 countries, focuses on ophthalmic diseases, orphan conditions and acute care hospital products. For more information, see

* Some patients may require the flexibility of twice-daily dosing for optimal results.

**Dr. Penny Asbell is a member of Aton's Advisory Board and received an unrestricted grant in 2008 from Aton for her research.

SOURCE Aton Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New Momentum Launches Anti-Counterfeiting Software for Pharmaceutical Companies
2. Otsuka America Pharmaceutical, Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc. Announce Restructuring Changes Aimed at Growing Otsukas Pharmaceutical Business Worldwide
3. Market for Niche Blockbusters Promises an Attractive Future for Large Pharmaceutical Companies, Indicates Frost & Sullivan
4. Pharmacyclics Receives Nasdaq Notification
5. Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
6. Transdel Pharmaceuticals, Inc. Featured on National Broadcast Television
7. Update: Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results
8. Vanda Pharmaceuticals Responds to Announcement and Filing by a Group Led by Tang Capital Partners, LP
9. Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results
10. Nostrum Pharmaceuticals Obtains Worldwide Licensing Rights From IMTECH for Clinical Development of the Small Molecule Caerulomycin and Its Proprietary Derivatives for Their Novel Indication of Immunosuppression
11. As a Result of the Jupiter Trial, 65 Percent of Surveyed MCO Pharmacy Directors Will Reimburse Crestor for Patients with Elevated hsCRP
Post Your Comments:
(Date:10/12/2015)... NJ (PRWEB) , ... October 12, 2015 , ... The ... programs and initiatives focused on improving public health and enhancing the quality of life ... will go to 11 New Jersey non-profit organizations. , The charitable arm of ...
(Date:10/12/2015)... ... October 12, 2015 , ... Advera Health Analytics, Inc . ... qualified Managed Care Organizations (MCOs) in order to provide health plans, payers, systems, and ... making process. In addition, the DSM is also being offered to healthcare media organizations ...
(Date:10/12/2015)... ... October 12, 2015 , ... A new invention has just been ... An inventor from Rutland, Mass., has modified a conventional nasal aspirator with child safety ... in withdrawing mucus from sinuses and nasal passages more safely and effectively than with ...
(Date:10/12/2015)... , ... October 12, 2015 , ... NFL football fans who are interested in having ... a great cause. CLICK HERE to donate to Smile for a Lifetime (S4L) ... to win an all-inclusive trip to the 2016 NFL Super Bowl! , Donors contributing $20.00 ...
(Date:10/12/2015)... York, NY (PRWEB) , ... October 12, 2015 ... ... Inc., Care to Care has secured a new corporate headquarters, located at 485 ... will allow for improved workflow and increased emphasis on cloud-based technology. , “Care ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... ) ... "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic ... Industry Trends, Technologies, Participants, and Environment" ... ) has announced the addition of ... Companion Diagnostic Market to 2019 - Strategic ...
(Date:10/12/2015)... St. Paul, Minn. , Oct. 12, 2015 /PRNewswire/ ... with it, a need to help integrate these devices ... global leader of ergonomic healthcare mounting and mobility solutions, ... Carts, its lightest cart yet, for a wide array ... StyleView S-Tablet Cart SV10 was developed exclusively for Microsoft ...
(Date:10/12/2015)... 12, 2015 ... grow at 7.2% CAGR, microscopy market growth ... focus on nanotechnology, technological advancements, and increasing ... available with ... --> Complete report on microscopy ...
Breaking Medicine Technology: